Sermorelin (GHRH 1-29)

Sermorelin is a synthetic peptide that is a structural analogue of the endogenous Growth Hormone-Releasing Hormone (GHRH). Specifically, it consists of the first 29 amino acids of the human GHRH polypeptide chain, representing the shortest fully functional fragment of the native hormone.

Its mechanism of action involves binding to and stimulating the GHRH receptors located in the anterior pituitary gland. This action mimics the function of endogenous GHRH, signaling the pituitary to synthesize and secrete the body's own supply of growth hormone (GH) in a pulsatile manner that reflects natural physiological rhythms. Sermorelin is characterized by a very short biological half-life of approximately 10-12 minutes, as it is rapidly degraded in the bloodstream. This short duration is what preserves the natural, pulsatile release of GH.

Sermorelin Acetate received FDA approval for the diagnosis and treatment of pediatric growth hormone deficiency. While it has been largely superseded by recombinant HGH for that specific indication, it is currently utilized in clinical settings, often for managing age-related decline in adult growth hormone levels, as it promotes the body's own production of GH rather than directly replacing it.